Next book

THE TRUTH IN SMALL DOSES

WHY WE'RE LOSING THE WAR ON CANCER—AND HOW TO WIN IT

An important evaluative study meriting serious public discussion.

We cannot rely on advances in molecular biology to beat the scourge of cancer. So argues journalist Leaf, who got interested in the subject via the impressive success story of the drug Gleevec, which effectively delivers targeted cancer therapy to certain leukemia patients.

This was a special circumstance, the author learned after meeting the CEO of Novartis, the company that developed the drug, in 2002; Gleevec represented a radical therapeutic advance, but most cancers are more complex than leukemia. Even though his professional expertise was in finance and business journalism rather than science (he has been executive editor of Fortune and other magazines), Leaf was fascinated by the implications of this story; since then, he has conducted interviews with more than 1,000 people, including oncologists, geneticists, doctors and patients. Over time, he writes, he came to understand that there was no quick fix for cancer. While advances in oncology, especially early diagnosis, have reduced the risk of dying from cancer, the incidence of cancer is increasing as the population ages, imposing a growing social burden. More Americans will die from cancer over the next 15 months than the total of combat fatalities since 1775, writes Leaf, attributing that daunting statistic to a dysfunctional "cancer culture.” He dates the problem to the National Cancer Act, passed in response to President Richard Nixon's call for a war on cancer. Funding was increased, but rather than establish an institution modeled on NASA, dedicated solely to eradicating cancer, Congress assigned the responsibility to the National Institutes of Health, with a mandate to support university research through competitive public/private partnerships. This system fosters bureaucratic inertia and aversion to risk. While hopeful that future scientific advances will occur, Leaf believes that the system must be revamped now, arguing that free exchange of information and a major upgrade in preventative medicine are the keys to improvement.

An important evaluative study meriting serious public discussion.

Pub Date: July 16, 2013

ISBN: 978-1-4767-3998-4

Page Count: 480

Publisher: Simon & Schuster

Review Posted Online: June 7, 2013

Kirkus Reviews Issue: June 15, 2013

Categories:
Next book

THE ELEMENTS OF STYLE

50TH ANNIVERSARY EDITION

Stricter than, say, Bergen Evans or W3 ("disinterested" means impartial — period), Strunk is in the last analysis...

Privately published by Strunk of Cornell in 1918 and revised by his student E. B. White in 1959, that "little book" is back again with more White updatings.

Stricter than, say, Bergen Evans or W3 ("disinterested" means impartial — period), Strunk is in the last analysis (whoops — "A bankrupt expression") a unique guide (which means "without like or equal").

Pub Date: May 15, 1972

ISBN: 0205632645

Page Count: 105

Publisher: Macmillan

Review Posted Online: Oct. 28, 2011

Kirkus Reviews Issue: May 1, 1972

Categories:
Next book

NUTCRACKER

This is not the Nutcracker sweet, as passed on by Tchaikovsky and Marius Petipa. No, this is the original Hoffmann tale of 1816, in which the froth of Christmas revelry occasionally parts to let the dark underside of childhood fantasies and fears peek through. The boundaries between dream and reality fade, just as Godfather Drosselmeier, the Nutcracker's creator, is seen as alternately sinister and jolly. And Italian artist Roberto Innocenti gives an errily realistic air to Marie's dreams, in richly detailed illustrations touched by a mysterious light. A beautiful version of this classic tale, which will captivate adults and children alike. (Nutcracker; $35.00; Oct. 28, 1996; 136 pp.; 0-15-100227-4)

Pub Date: Oct. 28, 1996

ISBN: 0-15-100227-4

Page Count: 136

Publisher: Harcourt

Review Posted Online: May 19, 2010

Kirkus Reviews Issue: Aug. 15, 1996

Categories:
Close Quickview